Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low,

Humans Carcinoma, Non-Small-Cell Lung / immunology Lung Neoplasms / immunology Kelch-Like ECH-Associated Protein 1 / genetics B7-H1 Antigen / genetics Female Mutation Disease Progression Middle Aged Biomarkers, Tumor
NSCLC case report chemoimmunotherapy cold tumor metastatic NSCLC neoantigen pseudoprogression tumor neoantigen

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 24 05 2024
accepted: 19 07 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: epublish

Résumé

A patient with a PD-L1-negative, TMB-low,

Identifiants

DOI: 10.3389/fimmu.2024.1437961 PMID: 39170614 PMC: PMC11335479
pubmed: 39170614
doi: 10.3389/fimmu.2024.1437961
pmc: PMC11335479
doi:

Substances chimiques

Kelch-Like ECH-Associated Protein 1 0
B7-H1 Antigen 0
KEAP1 protein, human 0
CD274 protein, human 0
Biomarkers, Tumor 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1437961

Informations de copyright

Copyright © 2024 Roussot, Thibaudin, Fumet, Daumoine, Hampe, Rébé, Limagne, Lagrange, Herreros, Lecuelle, Mananet, Ilie, Rageot, Boidot, Goussot, Comte, Jacob, Beltjens, Bergeron, Charon-Barra, Arnould, Derangère, Ladoire, Truntzer and Ghiringhelli.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Nicolas Roussot (N)

Unité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.
Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Marion Thibaudin (M)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Jean-David Fumet (JD)

Unité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.
Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Susy Daumoine (S)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Léa Hampe (L)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Cédric Rébé (C)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Emeric Limagne (E)

Unité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Aurélie Lagrange (A)

Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Victor Herreros (V)

Department of Interventional Radiology, Centre Georges-François Leclerc, Dijon, France.

Julie Lecuelle (J)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Hugo Mananet (H)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Alis Ilie (A)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

David Rageot (D)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Romain Boidot (R)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Vincent Goussot (V)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.

Anthony Comte (A)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.

Pierre Jacob (P)

Unité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.
Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Françoise Beltjens (F)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.

Anthony Bergeron (A)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.

Céline Charon-Barra (C)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.

Laurent Arnould (L)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.

Valentin Derangère (V)

Unité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

Sylvain Ladoire (S)

Unité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.
Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Caroline Truntzer (C)

Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

François Ghiringhelli (F)

Unité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Cancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Equipe Therapies and Immune Response in Cancers (TIRECS), Centre de Recherche INSERM LNC-UMR1231, Dijon, France.
Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Case report: Immune response characterization...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Case report: Immune response characterization...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Case report: Immune response characterization...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Protéine-1 de type kelch associée à ECH › Case report: Immune response characterization...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Case report: Immune response characterization...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Case report: Immune response characterization...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Case report: Immune response characterization...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Case report: Immune response characterization...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Case report: Immune response characterization...